One of Emma Walmsley's former lieutenants calls for GlaxoSmithKline chief to be given more time as she comes under pressure from hedge fund
One of Emma Walmsley's former lieutenants has called for the GlaxoSmithKline chief to be given more time as she comes under pressure from a US hedge fund.
Amir Reichman – a GSK director under Walmsley for four years – said: 'I admire her skills in managing the direction of the company and improving its innovation and culture'.
Under pressure: Emma Walmsley has faced scrutiny since it emerged Elliott Management had taken a multibillion-pound stake in GSK in April
In charge since 2017, she has faced scrutiny since it emerged Elliott Management had taken a multibillion-pound stake in GSK in April.
The hedge fund is yet to make its intentions public, but The Mail on Sunday has revealed it has had talks with major investors and asked whether she is the right person to lead the firm.
Reichman, chief executive of Israeli firm BiondVax Pharmaceuticals, was head of GSK's global vaccines engineering core technologies until earlier this year.
He said: 'She needs up to ten years. It is too big a behemoth to change the direction easily. She needs at least a few more years to see her work through.'
- Guides for my finances
- The best savings rates
- Best cash Isas
- A better bank account
- A cheaper mortgage
- The best DIY investing platform
- The best credit cards
- A cheaper energy deal
- Better broadband and TV deals
- Cheaper car insurance
- Stock market data
- Power Portfolio investment tracker
- This is Money's newsletter
- This is Money's podcast
- Investing Show videos
- Help from This is Money
- Financial calculators
This is Money's brilliant guide now available on the Kindle
